Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue

Podolsky, 2002, Inflammatory bowel disease, N Engl J Med, 347, 417, 10.1056/NEJMra020831

Sartor, 2010, Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis, Gastroenterology, 139, 1816, 10.1053/j.gastro.2010.10.036

Keely, 2009, Dexamethasone–pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers, J Control Release, 135, 35, 10.1016/j.jconrel.2008.12.001

Podolsky, 2003, The future of IBD treatment, J Gastroenterol, 38, 63

Talley, 2011, An evidence-based systematic review on medical therapies for inflammatory bowel disease, Am J Gastroenterol, 106, S2, 10.1038/ajg.2011.58

Byrne, 2007, Patient preferences between surgical and medical treatment in Crohn's disease, Dis Colon Rectum, 50, 586, 10.1007/s10350-006-0847-0

Yang, 2002, Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation, Int J Pharm, 235, 1, 10.1016/S0378-5173(02)00004-2

Sandborn, 2002, Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis, Am J Gastroenterol, 97, 2939, 10.1111/j.1572-0241.2002.07092.x

Hanauer, 2004, COLAL-PRED Alizyme, Curr Opin Investig Drugs, 5, 1192

Steed, 1997, The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system (“TIME CLOCK (R)” system), J Control Release, 49, 115, 10.1016/S0168-3659(97)00062-X

Hebden, 2000, Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis, Aliment Pharmacol Ther, 14, 155, 10.1046/j.1365-2036.2000.00697.x

Hua, 2014, Orally administered liposomal formulations for colon targeted drug delivery, Front Pharmacol, 5, 1, 10.3389/fphar.2014.00138

Laroui, 2010, Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model, Gastroenterology, 138, 843, 10.1053/j.gastro.2009.11.003

Coco, 2013, Drug delivery to inflamed colon by nanoparticles: comparison of different strategies, Int J Pharm, 440, 3, 10.1016/j.ijpharm.2012.07.017

Asghar, 2006, Multiparticulate formulation approach to colon specific drug delivery: current perspectives, J Pharm Pharm Sci, 9, 327

Hu, 2000, Application of a biomagnetic measurement system (BMS) to the evaluation of gastrointestinal transit of intestinal pressure-controlled colon delivery capsules (PCDCs) in human subjects, Pharm Res, 17, 160, 10.1023/A:1007561129221

Coupe, 1991, Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects, Pharm Res, 8, 360, 10.1023/A:1015849700421

Rao, 2004, Objective evaluation of small bowel and colonic transit time using pH telemetry in athletes with gastrointestinal symptoms, Br J Sports Med, 38, 482, 10.1136/bjsm.2003.006825

Buhmann, 2007, Assessment of colonic transit time using MRI: a feasibility study, Eur Radiol, 17, 669, 10.1007/s00330-006-0414-z

Sathyan, 2000, Effect of dosing time on the total intestinal transit time of non-disintegrating systems, Int J Pharm, 204, 47, 10.1016/S0378-5173(00)00472-5

Fallingborg, 1993, Very low intraluminal colonic pH in patients with active ulcerative colitis, Dig Dis Sci, 38, 1989, 10.1007/BF01297074

Bratten, 2006, New directions in the assessment of gastric function: clinical applications of physiologic measurements, Dig Dis, 24, 252, 10.1159/000092878

Nugent, 2001, Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs, Gut, 48, 571, 10.1136/gut.48.4.571

Sasaki, 1997, Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease, Am J Gastroenterol, 92, 114

Ibekwe, 2008, Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems, Pharm Res, 25, 1828, 10.1007/s11095-008-9580-9

Nyhof, 1985, Effect of atropine on digested food-induced intestinal hyperemia, Am J Physiol, 249, G685

Fatouros, 2008, In vitro lipid digestion models in design of drug delivery systems for enhancing oral bioavailability, Expert Opin Drug Metab Toxicol, 4, 65, 10.1517/17425255.4.1.65

Keely, 2011, Chloride-led disruption of the intestinal mucous layer impedes Salmonella invasion: evidence for an ‘enteric tear’ mechanism, Cell Physiol Biochem, 28, 743, 10.1159/000335768

Sartor, 2008, Microbial influences in inflammatory bowel diseases, Gastroenterology, 134, 577, 10.1053/j.gastro.2007.11.059

Macfarlane, 2011, Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics, J Clin Gastroenterol, 45, S120, 10.1097/MCG.0b013e31822fecfe

Sinha, 2001, Polysaccharides in colon-specific drug delivery, Int J Pharm, 224, 19, 10.1016/S0378-5173(01)00720-7

Frank, 2007, Molecular–phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases, Proc Natl Acad Sci U S A, 104, 13780, 10.1073/pnas.0706625104

Albenberg, 2014, Diet and the intestinal microbiome: associations, functions, and implications for health and disease, Gastroenterology, 146, 1564, 10.1053/j.gastro.2014.01.058

Britton, 2014, Role of the intestinal microbiota in resistance to colonization by Clostridium difficile, Gastroenterology, 146, 1547, 10.1053/j.gastro.2014.01.059

Patel, 2014, Mucosal inflammatory response to Salmonella typhimurium infection, Front Immunol, 5, 311, 10.3389/fimmu.2014.00311

Grover, 2008, Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress, Neurogastroenterol Motil, 20, 998, 10.1111/j.1365-2982.2008.01142.x

Li, 2003, Basement membrane components, J Clin Pathol, 56, 885, 10.1136/jcp.56.12.885

Antoni, 2014, Intestinal barrier in inflammatory bowel disease, World J Gastroenterol, 20, 1165, 10.3748/wjg.v20.i5.1165

Rana, 2013, Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease, Dig Dis Sci, 58, 2594, 10.1007/s10620-013-2694-x

Kashyap, 2013, Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice, Gastroenterology, 144, 967, 10.1053/j.gastro.2013.01.047

Sartor, 2008, Therapeutic correction of bacterial dysbiosis discovered by molecular techniques, Proc Natl Acad Sci U S A, 105, 16413, 10.1073/pnas.0809363105

Linskens, 2001, The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics, Scand J Gastroenterol Suppl, 234, 29, 10.1080/003655201753265082

Keely, 2012, Activated fluid transport regulates bacterial–epithelial interactions and significantly shifts the murine colonic microbiome, Gut Microbes, 3, 250, 10.4161/gmic.20529

Musch, 2013, Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota, Dig Dis Sci, 58, 668, 10.1007/s10620-012-2509-5

Barkas, 2013, Electrolyte and acid–base disorders in inflammatory bowel disease, Ann Gastroenterol, 26, 23

Lucas, 1978, Acid microclimate in coeliac and Crohn's disease: a model for folate malabsorption, Gut, 19, 735, 10.1136/gut.19.8.735

McConnell, 2008, Gut instincts: explorations in intestinal physiology and drug delivery, Int J Pharm, 364, 213, 10.1016/j.ijpharm.2008.05.012

Van Citters, 2006, Ileal brake: neuropeptidergic control of intestinal transit, Curr Gastroenterol Rep, 8, 367, 10.1007/s11894-006-0021-9

Yang, 2008, Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora, J Control Release, 125, 77, 10.1016/j.jconrel.2007.10.026

Laukoetter, 2008, Role of the intestinal barrier in inflammatory bowel disease, World J Gastroenterol, 14, 401, 10.3748/wjg.14.401

Cunningham, 2012, Myosin light chain kinase: pulling the strings of epithelial tight junction function, Ann N Y Acad Sci, 1258, 34, 10.1111/j.1749-6632.2012.06526.x

Wang, 2010, Restoration of rat colonic epithelium after in situ intestinal instillation of the absorption promoter, sodium caprate, Ther Deliv, 1, 75, 10.4155/tde.10.5

Goggins, 2013, Hypoxia and integrin-mediated epithelial restitution during mucosal inflammation, Front Immunol, 4, 272, 10.3389/fimmu.2013.00272

Comerford, 2002, Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene, Cancer Res, 62, 3387

Creed, 2007, Review article: steroid resistance in inflammatory bowel disease—mechanisms and therapeutic strategies, Aliment Pharmacol Ther, 25, 111, 10.1111/j.1365-2036.2006.03156.x

Dong, 2009, Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP, Cancer Res, 69, 3918, 10.1158/0008-5472.CAN-08-2747

Schmidt, 1996, Effect of intestinal resection on human small bowel motility, Gut, 38, 859, 10.1136/gut.38.6.859

Spiller, 1988, Further characterisation of the ‘ileal brake’ reflex in man—effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY, Gut, 29, 1042, 10.1136/gut.29.8.1042

Fallingborg, 1998, Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease, Dig Dis Sci, 43, 702, 10.1023/A:1018893409596

Gracie, 2012, Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea, Neurogastroenterol Motil, 24, 983-e538, 10.1111/j.1365-2982.2012.01953.x

Thompson, 1998, Role of the ileocecal junction in the motor response to intestinal resection, J Gastrointest Surg, 2, 174, 10.1016/S1091-255X(98)80010-3

Ammon, 1974, Inhibition of ileal water absorption by intraluminal fatty acids. Influence of chain length, hydroxylation, and conjugation of fatty acids, J Clin Invest, 53, 205, 10.1172/JCI107539

Watts, 1992, The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis, Int J Pharm, 87, 215, 10.1016/0378-5173(92)90245-W

Van Citters, 1999, The ileal brake: a fifteen-year progress report, Curr Gastroenterol Rep, 1, 404, 10.1007/s11894-999-0022-6

Lin, 2005, Measurement of gastrointestinal transit, Dig Dis Sci, 50, 989, 10.1007/s10620-005-2694-6

Malayandi, 2014, Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease, Drug Deliv Transl Res, 4, 187, 10.1007/s13346-013-0185-4

Xiao, 2012, Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease, Expert Opin Drug Deliv, 9, 1393, 10.1517/17425247.2012.730517

Collnot, 2012, Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa, J Control Release, 161, 235, 10.1016/j.jconrel.2012.01.028

Lamprecht, 2005, Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats, J Pharmacol Exp Ther, 315, 196, 10.1124/jpet.105.088146

Beloqui, 2013, Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis, Int J Pharm, 454, 775, 10.1016/j.ijpharm.2013.05.017

Hillyer, 2001, Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles, J Pharm Sci, 90, 1927, 10.1002/jps.1143

des Rieux, 2005, Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium, Eur J Pharm Sci, 25, 455, 10.1016/j.ejps.2005.04.015

Pichai, 2012, Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases, World J Gastroenterol, 18, 2895, 10.3748/wjg.v18.i23.2895

Lamprecht, 2001, Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa, Pharm Res, 18, 788, 10.1023/A:1011032328064

Lamprecht, 2010, IBD: selective nanoparticle adhesion can enhance colitis therapy, Nat Rev Gastroenterol Hepatol, 7, 311, 10.1038/nrgastro.2010.66

Wachsmann, 2013, Surfactant-dependence of nanoparticle treatment in murine experimental colitis, J Control Release, 172, 62, 10.1016/j.jconrel.2013.07.031

Schmidt, 2013, Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients, J Control Release, 165, 139, 10.1016/j.jconrel.2012.10.019

Han, 2012, Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system, Eur J Pharm Sci, 46, 500, 10.1016/j.ejps.2012.04.002

Liu, 2005, Interaction of various pectin formulations with porcine colonic tissues, Biomaterials, 26, 5907, 10.1016/j.biomaterials.2005.03.005

Larsson, 2009, A complex, but uniform O-glycosylation of the human MUC2 mucin from colonic biopsies analyzed by nanoLC/MSn, Glycobiology, 19, 756, 10.1093/glycob/cwp048

Urayama, 1997, Mechanisms and treatment of diarrhea in inflammatory bowel diseases, Inflamm Bowel Dis, 3, 114, 10.1097/00054725-199706000-00006

Niebel, 2012, Nanoparticle-based clodronate delivery mitigates murine experimental colitis, J Control Release, 160, 659, 10.1016/j.jconrel.2012.03.004

Lautenschlager, 2013, PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease, Eur J Pharm Biopharm, 85, 578, 10.1016/j.ejpb.2013.09.016

Gradauer, 2013, Liposomes coated with thiolated chitosan enhance oral peptide delivery to rats, J Control Release, 172, 872, 10.1016/j.jconrel.2013.10.011

Manconi, 2013, Improving oral bioavailability and pharmacokinetics of liposomal metformin by glycerolphosphate–chitosan microcomplexation, AAPS PharmSciTech, 14, 485, 10.1208/s12249-013-9926-4

Takeuchi, 2003, Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats, J Control Release, 86, 235, 10.1016/S0168-3659(02)00411-X

Gradauer, 2012, Chemical coupling of thiolated chitosan to preformed liposomes improves mucoadhesive properties, Int J Nanomedicine, 7, 2523

Thirawong, 2008, Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin–liposome nanocomplexes, J Control Release, 125, 236, 10.1016/j.jconrel.2007.10.023

Tirosh, 2009, Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa, Mol Pharm, 6, 1083, 10.1021/mp9000926

Carlson, 1999, Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion, Am J Gastroenterol, 94, 1876, 10.1111/j.1572-0241.1999.01223.x

Peterson, 2002, A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease, Am J Gastroenterol, 97, 1755, 10.1111/j.1572-0241.2002.05837.x

Lamprecht, 2001, Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease, J Pharmacol Exp Ther, 299, 775

Jubeh, 2004, Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes, Pharm Res, 21, 447, 10.1023/B:PHAM.0000019298.29561.cd

Muchow, 2008, Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery, Drug Dev Ind Pharm, 34, 1394, 10.1080/03639040802130061

Beloqui, 2014, Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution, J Microencapsul, 31, 1, 10.3109/02652048.2013.788090

Meissner, 2006, Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery, Int J Pharm, 316, 138, 10.1016/j.ijpharm.2006.01.032

Cu, 2008, Controlled surface modification with poly(ethylene) glycol enhances diffusion of PLGA nanoparticles in human cervical mucus, Mol Pharm, 6, 173, 10.1021/mp8001254

Tang, 2009, Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier, Proc Natl Acad Sci U S A, 106, 19268, 10.1073/pnas.0905998106

Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv Drug Deliv Rev, 61, 158, 10.1016/j.addr.2008.11.002

Vong, 2012, An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice, Gastroenterology, 143, 1027, 10.1053/j.gastro.2012.06.043

Ju, 2009, A gamma-tocopherol-rich mixture of tocopherols inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sulfate sodium-treated mice, Cancer Prev Res (Phila), 2, 143, 10.1158/1940-6207.CAPR-08-0099

Jin, 2008, American ginseng suppresses inflammation and DNA damage associated with mouse colitis, Carcinogenesis, 29, 2351, 10.1093/carcin/bgn211

Kotakadi, 2008, Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis, Carcinogenesis, 29, 1799, 10.1093/carcin/bgn143

Tobio, 2000, The role of PEG on the stability in digestive fluids and in vivo fate of PEG–PLA nanoparticles following oral administration, Colloids Surf B: Biointerfaces, 18, 315, 10.1016/S0927-7765(99)00157-5

Ashford, 1993, An in vivo investigation into the suitability of pH dependent polymers for colonic targeting, Int J Pharm, 95, 193, 10.1016/0378-5173(93)90406-6

Karn, 2011, Mucoadhesive liposomal delivery systems: the choice of coating material, Drug Dev Ind Pharm, 37, 482, 10.3109/03639045.2010.523425

Haznedar, 2004, Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide, Int J Pharm, 269, 131, 10.1016/j.ijpharm.2003.09.015

Barea, 2012, Encapsulation of liposomes within pH responsive microspheres for oral colonic drug delivery, Int J Biomater, 1, 10.1155/2012/458712

Barea, 2010, Evaluation of liposomes coated with a pH responsive polymer, Int J Pharm, 402, 89, 10.1016/j.ijpharm.2010.09.028

Makhlof, 2009, pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model, Eur J Pharm Biopharm, 72, 1, 10.1016/j.ejpb.2008.12.013

Kshirsagar, 2012, Preparation and characterization of nanocapsules for colon-targeted drug delivery system, Pharm Dev Technol, 17, 607, 10.3109/10837450.2011.557732

Legrand, 1999, Polymeric nanocapsules as drug delivery systems, STP Pharm Sci, 9, 411

Ali, 2014, Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases, J Control Release, 183, 167, 10.1016/j.jconrel.2014.03.039

Beloqui, 2014, pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease, Int J Pharm, 473, 203, 10.1016/j.ijpharm.2014.07.009

Lamprecht, 2005, A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles, J Control Release, 104, 337, 10.1016/j.jconrel.2005.02.011

Laroui, 2014, Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles, Mol Ther, 22, 69, 10.1038/mt.2013.214

Xiao, 2014, Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice, Gastroenterology, 146, 1289, 10.1053/j.gastro.2014.01.056

Kriegel, 2011, Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease, J Control Release, 150, 77, 10.1016/j.jconrel.2010.10.002

Kriegel, 2011, Dual TNF-alpha/cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease, Clin Transl Gastroenterol, 2, e2, 10.1038/ctg.2011.1

Bhavsar, 2007, Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS), J Control Release, 119, 339, 10.1016/j.jconrel.2007.03.006

Moulari, 2008, The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis, Biomaterials, 29, 4554, 10.1016/j.biomaterials.2008.08.009

Li, 2004, Fabrication of porous hollow silica nanoparticles and their applications in drug release control, J Control Release, 98, 245, 10.1016/j.jconrel.2004.04.019

Lih-Brody, 1996, Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease, Dig Dis Sci, 41, 2078, 10.1007/BF02093613

Simmonds, 1992, Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease, Gastroenterology, 103, 186, 10.1016/0016-5085(92)91112-H

Mahida, 1989, Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease, Gut, 30, 1362, 10.1136/gut.30.10.1362

Wilson, 2010, Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines, Nat Mater, 9, 923, 10.1038/nmat2859

Leirdal, 2002, Gene silencing in mammalian cells by preformed small RNA duplexes, Biochem Biophys Res Commun, 295, 744, 10.1016/S0006-291X(02)00736-2

Zhang, 2007, Cationic lipids and polymers mediated vectors for delivery of siRNA, J Control Release, 123, 1, 10.1016/j.jconrel.2007.07.016

Thiele, 2001, Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?, J Control Release, 76, 59, 10.1016/S0168-3659(01)00412-6

Hua, 2013, Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies, Front Pharmacol, 4, 127, 10.3389/fphar.2013.00127

Sofou, 2008, Antibody-targeted liposomes in cancer therapy and imaging, Expert Opin Drug Deliv, 5, 189, 10.1517/17425247.5.2.189

Willis, 1998, Ligand-targeted liposomes, Adv Drug Deliv Rev, 29, 249, 10.1016/S0169-409X(97)00083-5

Saltzman, 1994, Antibody diffusion in human cervical mucus, Biophys J, 66, 508, 10.1016/S0006-3495(94)80802-1

Mane, 2012, Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice, Int J Nanomedicine, 7, 4223

Sans, 1999, VCAM-1 and ICAM-1 mediate leukocyte–endothelial cell adhesion in rat experimental colitis, Gastroenterology, 116, 874, 10.1016/S0016-5085(99)70070-3

Danese, 2005, Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation, Dig Liver Dis, 37, 811, 10.1016/j.dld.2005.03.013

Binion, 1998, Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease, Lancet, 352, 1742, 10.1016/S0140-6736(98)05050-8

Binion, 1997, Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease, Gastroenterology, 112, 1895, 10.1053/gast.1997.v112.pm9178682

Bernstein, 1996, Beta 2-integrin/intercellular adhesion molecule (ICAM) expression in the normal human intestine, Clin Exp Immunol, 106, 160

Salmi, 1994, Aberrant binding of lamina propria lymphocytes to vascular endothelium in inflammatory bowel diseases, Gastroenterology, 106, 596, 10.1016/0016-5085(94)90691-2

Wileman, 1986, Identification of the macrophage mannose receptor as a 175-kDa membrane protein, Proc Natl Acad Sci U S A, 83, 2501, 10.1073/pnas.83.8.2501

van Vliet, 2008, Sweet preferences of MGL: carbohydrate specificity and function, Trends Immunol, 29, 83, 10.1016/j.it.2007.10.010

Xiao, 2013, Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy, Biomaterials, 34, 7471, 10.1016/j.biomaterials.2013.06.008

Zhang, 2013, Galactosylated trimethyl chitosan–cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages, Biomaterials, 34, 3667, 10.1016/j.biomaterials.2013.01.079

Laroui, 2014, Fab′-bearing siRNA TNFalpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis, J Control Release, 186, 41, 10.1016/j.jconrel.2014.04.046

Tacchini, 2008, Role of HIF-1 and NF-kappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals, J Biol Chem, 283, 20674, 10.1074/jbc.M800365200

Harel, 2011, Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa, PLoS One, 6, e24202, 10.1371/journal.pone.0024202

Xiao, 2014, Glycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticle, J Mater Chem B Mater Biol Med, 2, 1499, 10.1039/c3tb21564d

Kucharzik, 2005, Activation of epithelial CD98 glycoprotein perpetuates colonic inflammation, Lab Invest, 85, 932, 10.1038/labinvest.3700289

Nguyen, 2012, Homeostatic and innate immune responses: role of the transmembrane glycoprotein CD98, Cell Mol Life Sci, 69, 3015, 10.1007/s00018-012-0963-z